SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-16-746531
Filing Date
2016-10-25 16:01:55
Period of Report
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d275237d8k.htm 8-K 29095
2 EX-3.1 d275237dex31.htm EX-3.1 6273
3 EX-3.2 d275237dex32.htm EX-3.2 127732
  Complete submission text file 0001193125-16-746531.txt   165101
Mailing Address 7 HAMILTON LANDING SUITE 100 NOVATO CA 94949
Business Address 7 HAMILTON LANDING SUITE 100 NOVATO CA 94949 415-408-6200
Raptor Pharmaceutical Corp (Filer) CIK: 0001070698 (see all company filings)

IRS No.: 860883978 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-25571 | Film No.: 161950418
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences